Key result
Six gene biomarkers differentiate STEMI from stable CAD with AUC up to ~0.94.
Why the study?
The study aimed to reveal the underlying mechanisms of platelets in AMI and identify potential biomarkers that separate AMI from other cardiovascular diseases and healthy individuals.
Does platelet gene expression and immune cell infiltration profile differentiate acute ST-segment elevation myocardial infarction from stable coronary artery disease and healthy controls?
Cross-Sectional (n=52)
Does platelet gene expression and immune cell infiltration profile differentiate acute ST-segment elevation myocardial infarction from stable coronary artery disease and healthy controls?
Platelet gene expression profiling identified novel candidate molecular biomarkers, including ARG1 and NAMPTL, that may help rapidly distinguish acute STEMI from stable coronary artery disease.
Answers are grounded in this paper and cite their sources.
Identifies novel candidate biomarkers for distinguishing acute STEMI from stable CAD; leaves open their clinical utility.
Acute myocardial infarction (AMI) was considered a fatal disease resulting in high morbidity and mortality; platelet activation or aggregation plays a critical role in participating in the pathogenesis of AMI. The current study aimed to reveal the underlying mechanisms of platelets in the confrontation of AMI and potential biomarkers that separate AMI from other cardiovascular diseases and healthy people with bioinformatic strategies. Immunity analysis revealed that the neutrophil was significantly decreased in patients with SCAD compared with patients with ST-segment elevation myocardial infarction (STEMI) or healthy controls; monocytes and neutrophils showed potential in distinguishing patients with STEMI from patients with SCAD. Six differentially expressed genes (DEGs) showed great performances in differentiating STEMI patients from SCAD patients with AUC greater than 0.9. Correlation analysis showed that these six DEGs were significantly positively correlated with neutrophils; three genes were negatively correlated with monocytes. Weighted gene co-expression network analysis (WGCNA) found that module ‘royalblue’ had the highest correlation with STEMI; genes in STEMI-related module were enriched in cell–cell interactions, blood vessels’ biological processes, and peroxisome proliferator-activated receptor (PPAR) signaling pathway; four genes (FN1, CD34, LPL, and WWTR1) represented the capability of identifying patients with STEMI from healthy controls and patients with SCAD; two genes (ARG1 and NAMPTL) were considered as novel biomarkers for identifying STEMI from SCAD; FN1 represented the potential as a novel biomarker for STEMI. Our findings indicated that the distribution of neutrophils could be considered as a potential molecular trait for separating patients with STEMI from SCAD.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2021) conducted a cross-sectional in Acute Myocardial Infarction (AMI) and Stable Coronary Artery Disease (SCAD) (n=52). ST-segment elevation myocardial infarction (STEMI) vs. Stable coronary artery disease (SCAD) and healthy controls was evaluated on Diagnostic performance (AUC) of differentially expressed genes for differentiating STEMI from SCAD (p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: